1. Home
  2. NXT vs PODD Comparison

NXT vs PODD Comparison

Compare NXT & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NXT

Nextracker Inc.

N/A

Current Price

$113.61

Market Cap

15.1B

Sector

Technology

ML Signal

N/A

Logo Insulet Corporation

PODD

Insulet Corporation

N/A

Current Price

$238.10

Market Cap

17.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NXT
PODD
Founded
2013
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.1B
17.0B
IPO Year
2023
2007

Fundamental Metrics

Financial Performance
Metric
NXT
PODD
Price
$113.61
$238.10
Analyst Decision
Buy
Strong Buy
Analyst Count
19
20
Target Price
$105.50
$358.00
AVG Volume (30 Days)
1.7M
1.0M
Earning Date
04-27-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
2.97
N/A
EPS
2.86
3.48
Revenue
$2,959,197,000.00
$2,708,100,000.00
Revenue This Year
$19.73
$24.33
Revenue Next Year
$11.74
$19.33
P/E Ratio
$35.43
$68.27
Revenue Growth
18.38
30.73
52 Week Low
$36.06
$233.29
52 Week High
$131.59
$354.88

Technical Indicators

Market Signals
Indicator
NXT
PODD
Relative Strength Index (RSI) 54.19 37.50
Support Level $111.03 N/A
Resistance Level $130.17 $299.75
Average True Range (ATR) 5.56 7.33
MACD -1.02 0.36
Stochastic Oscillator 62.44 16.06

Price Performance

Historical Comparison
NXT
PODD

About NXT Nextracker Inc.

Nextpower (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextpower's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextpower has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Share on Social Networks: